A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumours.

Trial Profile

A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2014

At a glance

  • Drugs V 934; V 935
  • Indications Bladder cancer; Breast cancer; Colon cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 24 Apr 2012 Actual patient number is 37 according to ClinicalTrials.gov.
    • 19 May 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
    • 19 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top